ADJUVANT ATEZOLIZUMAB AFTER RADICAL RESECTION AND ADJUVANT CHEMOTHERAPY IN STAGE IB–IIIA NON-SMALL-CELL LUNG CANCER. IMPOWER010 CLINICAL TRIAL

Abstract

Novel adjuvant strategies are needed to optimise outcomes after complete surgical resection in patients with earlystage non-small-cell lung cancer (NSCLC). IMpower010 showed a disease-free survival benefit with atezolizumab versus best supportive care after adjuvant chemotherapy in patients with resected stage II–IIIA NSCLC, with pronounced benefit in the subgroup whose tumours expressed programmed death-ligand 1 (PD-L1) on 1% or more of tumour cells, and no new safety signals. Atezolizumab after adjuvant chemotherapy offers a promising treatment option for patients with resected early-stage NSCLC.